Ranked API manufacturers
01 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds 4 active US DMFs and 4 valid CEPs for everolimus, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
29 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF and one valid CEP for everolimus, filing since 2013. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 8 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
8 markets
03 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for everolimus, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 15 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
15 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for everolimus, filing since 2024. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
26 markets
05 China
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs and one valid CEP for everolimus, filing since 2017. Its GMP is recognised in 1 market.
Last FDA inspection
Not established
GMP recognised in
1 markets
06 Netherlands
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds one valid CEP for everolimus, filing since 2024. Its GMP is recognised in 14 markets.
Last FDA inspection
Not established
GMP recognised in
14 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds 3 active US DMFs for everolimus, filing since 2013. Its 2024 FDA inspection closed as VAI.
Last FDA inspection
2024 · VAI
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for everolimus, filing since 2019. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Last FDA inspection
2023 · VAI
GMP recognised in
1 markets
09 South Korea
Makes the API
Holds 2 active US DMFs for everolimus, filing since 2019. Its 2025 FDA inspection closed as VAI.
Last FDA inspection
2025 · VAI
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for everolimus, filing since 2015.
Last FDA inspection
Not established
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for everolimus, filing since 2012.
Last FDA inspection
Not established
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one valid CEP for everolimus, filing since 2025.
Last FDA inspection
Not established
GMP recognised in
Not established
9 more manufacturers hold filings for everolimus
The names are listed below. The filings, inspection history and GMP certificates behind
each one are available with a free account.
Open the full list with a free account Contract manufacturers (3)
Contract manufacturers make to order rather than holding their own filing for this
molecule.
Finished-dose makers (33)
How this list is built
The order is set by active filings weighted by regulator, inspection outcomes and their
recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags.
Every factor appears on the card it produced.
Read the full method.
- Active US DMFs
- FDA, List of Drug Master Files
- Valid CEPs
- EDQM certificate database
- Inspection outcomes
- FDA inspection classifications
- GMP certificates
- EudraGMDP and national regulators